CXCL10 and cancer: Cancer-associated death time was significantly longer in subjects with low levels of oncostatin, IP10 or NAP-2 (HR = 0.003; 95% CI: 0–925; p = 0.004, HR = 0.003; 95% CI: 0–925; p = 0.004, and HR = 0.014; 95% CI: 0–45; p = 0.04, respectively) (Figure 3G–L).